• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Galderma S.A. - Product Pipeline Review - Q4 2010 - Product Image

Galderma S.A. - Product Pipeline Review - Q4 2010

  • Published: December 2010
  • 52 pages
  • Global Markets Direct

Galderma S.A. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Galderma S.A. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Galderma S.A. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Galderma S.A. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- READ MORE >



List of Tables
List of Figures
Galderma S.A. Snapshot
Galderma S.A. Overview
Key Information
Key Facts
Galderma S.A. – Research and Development Overview
Key Therapeutic Areas
Galderma S.A. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Galderma S.A. – Pipeline Products Glance
Galderma S.A. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Galderma S.A. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Galderma S.A. – Drug Profiles
Differin + Tetralysal
Product Description
Mechanism of Action
R&D Progress
Epiudo + Doxycyline
Product Description
Mechanism of Action
R&D Progress
Asord
Product Description
Mechanism of Action
R&D Progress
CD 2027
Product Description
Mechanism of Action
R&D Progress
COL-121
Product Description
Mechanism of Action
R&D Progress
Galderma S.A. – Pipeline Analysis
Galderma S.A. – Pipeline Products by Therapeutic Class
Galderma S.A. Pipeline Products By Target
Galderma S.A. – Pipeline Products by Route of Administration
Galderma S.A. – Pipeline Products by Molecule Type
Galderma S.A. - Dormant Projects
Galderma S.A. – Company Statement
Galderma S.A. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 21, 2009: Galderma Receives Approval For Azzalure For Treatment Of Glabellar Lines In Spain
Jun 26, 2009: Galderma's Azzalure Receives Approval For Treatment Of Glabellar Lines In Germany
Mar 30, 2009: Galderma's Azzalure Receives Approval For Treatment Of Glabellar Lines In France
Mar 12, 2009: Galderma's Azzalure Receives Approval For Treatment Of Glabellar Lines In UK
Feb 02, 2009: Ipsen And Galderma Receive Approval For Azzalure In 15 European Countries
May 02, 2007: CollaGenex Pharmaceuticals Halts Trial Of Incyclinide Ffor The Treatment of Acne
Apr 15, 2005: CollaGenex Pharmaceuticals Reports Positive Outcome Of Phase II Clinical Study Evaluating COL-3 As A Treatment For Rosacea
Jan 22, 2003: QuatRx Pharmaceuticals Initiates Phase II Study Of Lead Compound In Patients With Psoriasis
Financial Deals Landscape
Galderma S.A., Deals Volume Summary, 2004 to YTD 2010
Galderma S.A., Deals Summary By Region, 2004 to YTD 2010
Galderma S.A., Deals Summary, 2004 to YTD 2010
Galderma S.A. Detailed Deal Summary
Asset Purchase
Galderma Acquires Metvix And Aktilite From PhotoCure
Acquisition
Galderma Acquires CollaGenex Pharmaceuticals
Foamix Extends Collaboration Agreement With Galderma Pharma
NovaBay Enters Into An Agreement With Galderma
Foamix And Galderma Sign An Agreement
Galderma Enters Into An Agreement With ZARS Pharma
Ipsen Extends Agreement With Galderma
Shionogi Signs Agreement With Galderma
Licensing Agreements
Galderma Enters Into A Licensing Agreement With PhotoCure
Ipsen Signs An Agreement With Galderma
Anika Therapeutics Enters Into Licensing Agreement With Galderma Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS